Phio Pharmaceuticals Corp (NASDAQ:PHIO) was the target of a large growth in short interest in the month of October. As of October 30th, there was short interest totalling 87,000 shares, a growth of 564.1% from the October 15th total of 13,100 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average daily volume of 450,600 shares, the days-to-cover ratio is currently 0.2 days.
A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. GSA Capital Partners LLP acquired a new position in shares of Phio Pharmaceuticals Corp (NASDAQ:PHIO) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,278 shares of the company’s stock, valued at approximately $46,000. GSA Capital Partners LLP owned approximately 0.37% of Phio Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 2.26% of the company’s stock.
NASDAQ PHIO traded down $0.03 on Tuesday, reaching $2.22. 250 shares of the stock traded hands, compared to its average volume of 678,015. The firm’s fifty day simple moving average is $2.18 and its 200 day simple moving average is $2.33. The company has a quick ratio of 10.33, a current ratio of 10.33 and a debt-to-equity ratio of 0.01. The company has a market cap of $13.01 million, a price-to-earnings ratio of -0.21 and a beta of 2.33. Phio Pharmaceuticals has a 12 month low of $1.60 and a 12 month high of $13.61.
Phio Pharmaceuticals (NASDAQ:PHIO) last issued its quarterly earnings results on Sunday, November 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). As a group, equities research analysts forecast that Phio Pharmaceuticals will post -2.23 EPS for the current fiscal year.
Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a research report on Friday, August 14th.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body.
Featured Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.